Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Jul 14;2(3):264-8.
doi: 10.1016/j.jdcr.2016.05.002. eCollection 2016 May.

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

Kathleen C Suozzi  1 , Maximilian Stahl  2 , Christine J Ko  1 , Anne Chiang  3 , Scott N Gettinger  3 , Mark D Siegel  2 , Christopher G Bunick  1
Affiliations
Case Reports

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

Kathleen C Suozzi et al. JAAD Case Rep. .
No abstract available

Keywords: CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; PD-1, programmed death–1; immune-related adverse events; immunotherapy; irAEs, immune-related adverse events; lung cancer; sarcoidosis.

PubMed Disclaimer

Figures

Fig 1
Fig 1
The spectrum of immune-related adverse events reported with checkpoint inhibitor therapy. The irAEs are graded based on severity from grade 1 to 4. Grade 2 to 3 reactions are typically managed by temporarily withholding medication with or without systemic corticosteroids. Grade 4 or grade 3 reaction that recurs is indication for discontinuing medication. Cutaneous irAEs can be managed with topical steroids if mild but may require systemic corticosteroids with long tapers to prevent recurrence. (*) indicates irAE reported in the literature in single case report. CN, Cranial nerve; GI, gastrointestinal.
Fig 2
Fig 2
Sarcoidosis in the setting of immune-related therapy for lung cancer. A, Distributed on the posterior neck and upper arms are greater than fifty 1- to 3-mm skin-colored to pink firm papules, in some areas coalescing into annular plaques. B, Dermal inflammatory infiltrate including relatively scant lymphocytes and epithelioid histiocytes arranged in well-defined granulomas. Giant cells are seen. There are no prominent epidermal changes. (Hematoxylin-eosin stain.)
See this image and copyright information in PMC

References

    1. Larkin J., Chiarion-Sileni V., Gonzalez R. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34. - PMC - PubMed
    1. Reule R.B., North J.P. Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol. 2013;69(5):e272–e273. - PubMed
    1. Eckert A., Schoeffler A., Dalle S., Phan A., Kiakouama L., Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 2009;218(1):69–70. - PubMed
    1. Vogel W.V., Guislain A., Kvistborg P., Schumacher T.N., Haanen J.B., Blank C.U. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol. 2012;30(2):e7–e10. - PubMed
    1. van den Eertwegh A.J., Versluis J., van den Berg H.P. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509–517. - PubMed

Publication types

LinkOut - more resources